Eradivir Secures $10.25M for Influenza Study
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
- Latest
- Trending
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
Medera aims for Nasdaq listing via SPAC to boost gene therapies, spotlighting rare biotech SPACs in 2024.
Boehringer Ingelheim acquires Saiba Animal Health, boosting pet R&D with innovative therapeutic vaccines.
AI SPERA partners with Hackers Central to introduce top-tier cyber solutions like 'Criminal IP ASM' to Mexico's security market.
Microsoft fixes zero-day flaw in Windows exploited by North Korea's Lazarus Group to gain system privileges.
Brain Cipher ransomware targets Indonesia, uses multiple identities to evade detection, causing disruptions.
Economist Alex Krüger predicts a swift recovery for crypto, dismissing fears of a protracted bear market similar to March 2020.
USX Cyber enhances GUARDIENT with advanced Mac protection, setting new standards in cybersecurity for macOS environments.
Discover GrimResource: A new hacking method exploiting Microsoft Management Console files. Learn how to protect yourself from this emerging threat.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.